Sign In
Buy AEZS
$5.72
+0 (+0%)
At Close: Nov 13, 2024
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
12:00pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerc
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
08:00am, Wednesday, 18'th May 2022
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
12:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook
12:05pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
– Continued advancement across diversified development pipeline
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
12:25pm, Monday, 02'nd May 2022 Zacks Investment Research
uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
12:05pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a neurodegenerative movement disorder
Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults
12:05pm, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
12:05pm, Tuesday, 12'th Apr 2022 GlobeNewswire Inc.
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
12:05pm, Monday, 11'th Apr 2022 GlobeNewswire Inc.
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
09:15pm, Monday, 21'st Mar 2022 Zacks Investment Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
12:05pm, Monday, 21'st Mar 2022 GlobeNewswire Inc.
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
12:25pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Lags Q4 Earnings Estimates
01:15pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
ANI (ANIP) delivered earnings and revenue surprises of -34.15% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Beholding Stock: Cinedigm Corp. (NASDAQ:CIDM), Aeterna Zentaris Inc. (NASDAQ:AEZS)
06:53am, Friday, 11'th Mar 2022 Stock Equity
Cinedigm Corp. (NASDAQ:CIDM) with the stream of -1.11% also noticed, India Aeterna Zentaris Inc. (NASDAQ:AEZS) encountered a rapid change of -0.97% in the last hour of Thursday’s trading session. Cinedigm … The post Beholding Stock: Cinedigm Corp. (NASDAQ:CIDM), Aeterna Zentaris Inc. (NASDAQ:AEZS) appeared first on Stocks Equity .
Aeterna Zentaris expands research program for COVID-19/Chlamydia vaccines
01:33pm, Thursday, 10'th Mar 2022 Seeking Alpha
Aeterna Zentaris (AEZS) expanded its existing research program with the Julius-Maximilians-University Wuerzburg ((JMU)) on the development of COVID-19 and Chlamydia…
